Focused on treatments for rare diseases, the company develops and commercializes therapies targeting serious conditions with limited treatment options. Its portfolio has included drugs for kidney and metabolic disorders, with revenue tied to a small number of specialty products and ongoing clinical ...
2 members of Congress have disclosed 13 trades in Retrophin Incorporated (RTRX), a Healthcare company. The buy/sell breakdown shows 10 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-03-20 | David P. Roe | buy | $1K – $15K |
| 2018-12-31 | David P. Roe | buy | $1K – $15K |
| 2018-12-03 | David P. Roe | buy | $1K – $15K |
| 2008-04-01 | MICHAEL T. MCCAUL | buy | — |
| 2008-04-01 | MICHAEL T. MCCAUL | sell | — |
| 2008-04-01 | MICHAEL T. MCCAUL | sell | — |
| 2008-02-05 | MICHAEL T. MCCAUL | buy | — |
| 2008-02-05 | MICHAEL T. MCCAUL | sell | — |
| 2007-11-07 | MICHAEL T. MCCAUL | buy | (64,529.10) |
| 2007-11-07 | MICHAEL T. MCCAUL | buy | $64,529.10 |
| 2007-10-08 | MICHAEL T. MCCAUL | buy | (43,676.38) |
| 2007-10-08 | MICHAEL T. MCCAUL | buy | $43,676.38 |
| 2007-07-06 | MICHAEL T. MCCAUL | buy | $75,657.84 |